Benchmark GlaxoSmithKline Plc Performance against Key Rivals.LYON, France -- Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue. GlaxoSmithKline plc company profile To order that report: www.reportlinker.com/p064471/GlaxoSmithKline- plc-PharmaVitae-Profile.html (Due to its length, this URL URL in full Uniform Resource Locator Address of a resource on the Internet. The resource can be any type of file stored on a server, such as a Web page, a text file, a graphics file, or an application program. may need to be copied/pasted into your Internet Internet Publicly accessible computer network connecting many smaller networks from around the world. It grew out of a U.S. Defense Department program called ARPANET (Advanced Research Projects Agency Network), established in 1969 with connections between computers at the browser's address field. Remove the extra space if one exists.) Introduction This analysis examines the historical and forecast performance for GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. for key drugs. An interactive forecasting and analysis tool provides continually con·tin·u·al adj. 1. Recurring regularly or frequently: the continual need to pay the mortgage. 2. updated quantitative and qualitative information. Scope Highlights Reasons to Purchase Benchmark GlaxoSmithKline's performance against key rivals in the ethical pharmaceutical sectorAnalyze the factors that will underscore The underscore character (_) is often used to make file, field and variable names more readable when blank spaces are not allowed. For example, NOVEL_1A.DOC, FIRST_NAME and Start_Routine. (character) underscore - _, ASCII 95. a forecast ethical pharmaceutical sales CAGR CAGR See: Compound Annual Growth Rate of -2.1% for GlaxoSmithKline over 2006-12Assess the generic threat faced by GlaxoSmithKline over the period 2006-12 and how this compares to generic risk across the Big Pharma peer set CHAPTER 1 EXECUTIVE SUMMARY 2 Key findings 2 Historical and forecast ethical sales performance 3 Therapeutic strategy 5 Launch and expiry outlook 10 Externalization The ability to easily connect to and transfer information between business partners. Increasingly, information systems are designed to make their data available to outside partners and customers. This type of collaboration is expected to be a vital part of IT in the 21st century. See EDI. , geographic and molecule type strategies 13 Externalization strategy 14 Geographic strategy 15 Molecule type strategy 16 SWOT analysis SWOT Analysis A tool that identifies the strengths, weaknesses, opportunities and threats of an organization. 17 Strengths 17 Weaknesses 18 Opportunities 19 Threats 21 CHAPTER 2 CORPORATE HISTORY 24 Key findings 24 Background 25 M&A history 25 Wellcome 25 Glaxo 25 Glaxo Wellcome 26 Beecham 26 Smith Kline 26 SmithKline Beecham 27 Key historical drug launches by component GSK companies 28 M&A strategy 29 R&D overview 32 Current corporate structure 34 CHAPTER 3 HISTORICAL PERFORMANCE 35 Key findings 35 Introduction 36 Revenue and growth rate analysis, 2001-06 36 Revenue and growth rate vs. peer set 37 Product analysis, 2001-06 39 Growth drivers 39 Seretide/Advair 39 Avandia Avandia® Rosiglitazone Diabetes An agent used with conventional therapy as a first-line monotherapy for type 2 diabetes. See Type 2 diabetes. 40 Flixotide 40 Lamictal Lamictal® Lamotrigine Neurology An adjunct agent for treating generalized seizures in Lennox-Gastaut syndrome. See Lennox-Gastaut syndrome. 40 Growth resistors 40 Seroxat Seroxat Paroxetine, see there 40 Augmentin Aug·men·tin A trademark for a preparation of amoxicillin and clavulanic acid. amoxicillin and clavulanate potassium 41 Serevent Ser·e·vent A trademark for the drug salmeterol xinafoate. salmeterol xinafoate Serevent (UK), Serevent Diskus Pharmacologic class: Beta2-adrenergic receptor agonist (long-acting) 41 Operating revenue operating revenue Revenue from any regular source. Revenue from sales is adjusted for discounts and returns when calculating operating revenue. Compare other revenue. and cost analysis, 2001-06 42 Operating revenue/cost analysis 43 CHAPTER 4 FORECAST PERFORMANCE 45 Key findings 45 Introduction 46 Revenue and growth rate, 2006-12 46 Product analysis, 2006-12 48 Growth drivers 53 Tykerb 53 Cervarix 54 Growth resistors 54 Seretide/Advair 54 Avandia 55 Wellbutrin Well·bu·trin A trademark for the drug bupropion hydrochloride, used to treat depression. bupropion hydrochloride Budeprion SR, Budeprion XL, Wellbutrin, Wellbutrin SR, Wellbutrin XL, Zyban 55 Zofran Zofran® Ondansetron Therapeutics An orally disintegrating tablet–ODT indicated for preventing RT and chemoherapy-induced and postoperative N&V. See Ondansetron. 56 Imigran 56 Therapy area analysis, 2006-12 58 Oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors. on·col·o·gy n. 61 Urology urology Medical specialty dealing with the urinary system and male reproductive organs. It traces its origin to medieval lithologists, itinerant healers who specialized in surgical removal of bladder stones. & sexual health 61 Infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. 62 Respiratory 62 CNS See Continuous net settlement. CNS See continuous net settlement (CNS). 62 Endocrine endocrine /en·do·crine/ (en´do-krin, en´do-krin) 1. secreting internally. 2. pertaining to internal secretions; hormonal. See also under system. en·do·crine adj. , metabolic met·a·bol·ic adj. Of, relating to, or resulting from metabolism. Metabolic Refers to the chemical processes of an organ or organism. & genetic disorders The following is a list of genetic disorders and their origins. Beside most disorders is a code that indicates the type of fertilization and the chromosome involved.
Therapy area focus 63 Launches and expiries analysis, 2006-12 68 Launch portfolio 69 Core portfolio 72 Expiry portfolio 74 Launch/core/expiry configuration 77 Externalization analysis, 2006-12 81 Geographic analysis, 2006-12 86 Molecule type analysis, 2006-12 89 CHAPTER 5 KEY PRODUCTS AND COMPETITORS 95 Key findings 95 Overview 96 Respiratory 97 Seretide/Advair 97 Overview 97 Sales forecast 98 Newsflow 98 Oncology 103 Tykerb 103 Overview 103 Sales forecast 104 Newsflow 104 Cervarix 107 Overview 107 Sales forecast 108 Newsflow 108 Zofran 112 Overview 112 Sales forecast 113 Newsflow 113 CNS 115 Lamictal 115 Overview 115 Sales forecast 116 Newsflow 116 Gepirone ER 119 Overview 119 Sales forecast 120 Newsflow 120 Trexima 122 Overview 122 Sales forecast 123 Newsflow 124 Wellbutrin 126 Overview 126 Sales forecast 127 Newsflow 127 Imigran 130 Overview 130 Sales forecast 131 Newsflow 131 Endocrine, metabolic & genetic disorders 133 Avandia 133 Overview 133 Sales forecast 134 Newsflow 135 Infectious disease 139 Rotarix 139 Overview 139 Sales forecast 140 Newsflow 140 CHAPTER 6 APPENDIX 143 IMS (1) See IP Multimedia Subsystem. (2) (Information Management System) An early IBM hierarchical DBMS for IBM mainframes. IMS was widely implemented throughout the 1970s under MVS and continues to be used under z/OS. vs. company-reported data reconciliation 143 References 146 Datamonitor reports 146 Abbreviations 146 Exchange rates 147 List of Tables Table 1: Peer set overview 37 Table 2: Operating revenue/cost analysis ($m), 2001-06 42 Table 3: Operating cost ratio analysis (% of total revenues), 2001-06 43 Table 4: Product portfolio overview, sales ($m), 2006-12 48 Table 5: Therapy area overview, sales ($m), 2006-12 58 Table 6: Launch portfolio overview, sales ($m), 2006-12 69 Table 7: Core portfolio overview, sales ($m), 2006-12 73 Table 8: Expiry portfolio overview, sales ($m), 2006-12 75 Table 9: Externally developed portfolio ($m), 2006-12 81 Table 10: Molecule type overview, sales ($m), 2006-12 89 Table 11: Key products overview 96 Table 12: Seretide/Advair: overview 97 Table 13: Seretide/Advair: sales forecast ($m), 2006-12 98 Table 14: Seretide/Advair: news flow 98 Table 15: Tykerb: overview 103 Table 16: Tykerb: sales forecast ($m), 2006-12 104 Table 17: Tykerb: news flow 104 Table 18: Cervarix: overview 107 Table 19: Cervarix: sales forecast ($m), 2006-12 108 Table 20: Cervarix: news flow 108 Table 21: Zofran: overview 112 Table 22: Zofran: sales forecast ($m), 2006-12 113 Table 23: Zofran: news flow 113 Table 24: Lamictal: overview 115 Table 25: Lamictal: sales forecast ($m), 2006-12 116 Table 26: Lamictal: news flow 116 Table 27: Gepirone ER: overview 119 Table 28: Gepirone ER: sales forecast ($m), 2006-12 120 Table 29: Gepirone ER: news flow 120 Table 30: Trexima: overview 122 Table 31: Trexima: sales forecast ($m), 2006-12 123 Table 32: Trexima: news flow 124 Table 33: Wellbutrin: overview 126 Table 34: Wellbutrin: sales forecast ($m), 2006-12 127 Table 35: Wellbutrin: news flow 127 Table 36: Imigran: overview 130 Table 37: Imigran: sales forecast ($m), 2006-12 131 Table 38: Imigran: news flow 131 Table 39: Avandia: overview 133 Table 40: Avandia: sales forecast ($m), 2006-12 134 Table 41: Avandia: news flow 135 Table 42: Rotarix: overview 139 Table 43: Rotarix: sales forecast ($m), 2006-12 140 Table 44: Rotarix: news flow 140 Table 45: Exchange rates, 2006 147 List of Figures Figure 1: Historical and forecast ethical sales performance (% CAGR), GSK and Big Pharma peer set 4 Figure 2: Therapeutic focus vs. Big Pharma peer set (%), 2006 6 Figure 3: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), GSK 10 Figure 4: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set 12 Figure 5: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2006 13 Figure 6: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2012 14 Figure 7: SWOT analysis of GSK 17 Figure 8: M&A/divestment history 27 Figure 9: Revenue & growth rate (ethical sales) ($m), 2001-06 36 Figure 10: Ethical revenue ($m) and growth rate (%) vs. peer set, 2001-06 38 Figure 11: Growth drivers/resistor products of historical revenue performance ($m), 2001-06 39 Figure 12: Operating revenue/cost analysis ($m), 2001-06 43 Figure 13: Operating cost ratio analysis (% of total revenues), 2001-06 44 Figure 14: Ethical revenue ($m) and growth rate (%), 2006-12 46 Figure 15: Top five products by sales ($m), 2006 51 Figure 16: Top five products by sales ($m), 2012 52 Figure 17: Growth drivers and resistors by product, 2006-12 53 Figure 18: Key strategic products, sales ($m), 2006-12 57 Figure 19: Ethical sales by therapy area ($m), 2006-12 59 Figure 20: Growth drivers and resistors by therapy area (%), 2006-12 61 Figure 21: Ethical sales by therapy area ($m), 2006-12 63 Figure 22: Therapy area focus compared with peer set (% total ethical sales), 2006 64 Figure 23: Therapy area focus compared with peer set (% total ethical sales), 2012 67 Figure 24: Launch schedule, sales ($m), 2006-12 71 Figure 25: Core products sales growth ($m), 2006-12 74 Figure 26: Expiry schedule, sales ($m), 2006-12 76 Figure 27: Launch, core and expiry, sales ($m), 2006-12 78 Figure 28: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), GlaxoSmithKline 79 Figure 29: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set 80 Figure 30: Externalization dependency, sales ($m), 2006-12 82 Figure 31: Growth drivers and resistors, externally vs. internally discovered products, sales ($m), 2006-12 83 Figure 32: Externalization dependency vs. peer set, % total sales, 2006 84 Figure 33: Externalization dependency vs. peer set, % total sales, 2012 85 Figure 34: Geographical sales breakdown ($m), 2006-12 86 Figure 35: Growth drivers and resistors by geography, sales ($m), 2006-12 87 Figure 36: US dependency vs. peer set, % total sales, 2006 88 Figure 37: US dependency vs. peer set, % total sales, 2012 89 Figure 38: Growth drivers and resistors by molecule type, sales ($m), 2006-12 91 Figure 39: Molecule type sales breakdown ($m), 2006-12 92 Figure 40: Biologics dependency vs. peer set, % total sales, 2006 93 Figure 41: Biologics dependency vs. peer set, % total sales, 2012 94 Figure 42: IMS vs. company-reported ethical sales discrepancy DISCREPANCY. A difference between one thing and another, between one writing and another; a variance. (q.v.) 2. Discrepancies are material and immaterial. ($m), 2006 144 Figure 43: IMS vs. company-reported ethical sales forecast growth rates Growth Rates The compounded annualized rate of growth of a company's revenues, earnings, dividends, or other figures. Notes: Remember, historically high growth rates don't always mean a high rate of growth looking into the future. (%), 2006-12 145 More market research reports? Go to http://www.reportlinker.com |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion